Vortioxetine News and Research

RSS

Antidepressant treatment may lead to improvements in sleep quality of patients with depression

In a study of 15 patients affected by major depressive disorder and complaining of insomnia, initiating treatment with vortioxetine for their depressive symptoms led to significant improvements in subjective sleep quality and daytime sleepiness.

17 Oct 2018

FDA's PDAC supports use of Brintellix for treating cognitive dysfunction in adults with MDD

Takeda Pharmaceutical Company Limited and H. Lundbeck A/S today announced that the U.S. Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee voted 8 to 2 that the companies presented substantial evidence to support the effectiveness of Brintellix (vortioxetine) for treating certain aspects of cognitive dysfunction in adults with Major Depressive Disorder (MDD).

5 Feb 2016

IQWiG dossier assessment finds no added benefit for vortioxetine in depression

Vortioxetine (trade name: Brintellix) has been approved since December 2013 for the treatment of depression in adults, but did not become actually available before May 2015. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this drug offers an added benefit over the appropriate comparator therapy. Such an added benefit cannot be derived from the dossier because it contained no data evaluable for the assessment.

12 Aug 2015

FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) announced today the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for review to add clinical data regarding the effect of Brintellix (vortioxetine) on certain aspects of cognitive function in adults with Major Depressive Disorder (MDD) to the current product label.

11 Aug 2015

FDA Approves Takeda-Lundbeck Drug For Major Depressive Disorder

...

1 Oct 2013

FDA Approves Takeda-Lundbeck Drug For Major Depressive Disorder

...

1 Oct 2013

FDA approves Brintellix drug to treat depressive disorder in adults

The U.S. Food and Drug Administration today approved Brintellix (vortioxetine) to treat adults with major depressive disorder.

1 Oct 2013

Takeda, Lundbeck announce presentation of data from four studies that evaluate vortioxetine for MDD

Takeda Pharmaceutical Company Limited and H. Lundbeck A/S today announced that the companies will be presenting new data from four studies that evaluated effectiveness in treating the overall symptoms of depression in patients taking vortioxetine, an investigational agent under review with the U.S. Food and Drug Administration for the treatment of major depressive disorder.

20 May 2013

Takeda, Lundbeck announce FDA acceptance of vortioxetine NDA submission

Takeda Global Research & Development Center, Inc., (Takeda) and H. Lundbeck A/S (Lundbeck) jointly announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing their submission of a New Drug Application (NDA) for vortioxetine for the treatment of major depressive disorder (MDD) in adult patients.

13 Dec 2012